Treatment of abnormal uterine bleeding with the gynecologic resectoscope.
The gynecologic resectoscope, recently approved by the Food and Drug Administration for the treatment of abnormal uterine bleeding, was evaluated for its success in the treatment of women with this complaint. Through June 1990, 216 patients were treated with this modality. Ninety were treated with transcervical myomectomy alone since they still desired fertility preservation or wished to avoid hysterectomy. Of the patients treated, 189 (87.5%) had follow-up evaluation for at least three months and some as long as three years. Of the ninety patients treated with resection of a submucous myoma, greater than 90% had a marked improvement in their symptoms, with decreased menstrual bleeding. Of the 96 patients treated with endometrial ablation, 50% were amenorrheic, 26% had hypomenorrhea, 17% had eumenorrhea, and 7% were unimproved. There was only one case of fluid overload, and no patients required a blood transfusion. Complications included two cases of endometritis and one perforation at the time of retrieval of myoma fragments. Four patients required placement of a 30-mL Foley catheter for control of postoperative bleeding. Gynecologic resectoscopy is a safe and effective alternative to major surgery in the management of abnormal uterine bleeding for which conservative measures have not been effective.
Serden
S P
SP
Department of Obstetrics and Gynecology, University of California School of Medicine, Los Angeles.
Brooks
P G
PG
D000328:Adult; D000368:Aged; D000568:Amenorrhea / Q000601:surgery*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002404:Catheterization; D003613:Danazol / Q000627:therapeutic use; D004564:Electrocoagulation / Q000295:instrumentation* / Q000379:methods; D004717:Endometrium / Q000601:surgery; D005260:Female; D006801:Humans; D020702:Hysteroscopes; D007889:Leiomyoma / Q000601:surgery; D016729:Leuprolide / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008599:Menstruation Disturbances / Q000601:surgery*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000601:surgery*; D014599:Uterus / Q000601:surgery*
D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide; D008525:Medroxyprogesterone; D003613:Danazol